Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2 Suppl):S281. Computed tomography (CT)-guided stereotactic radiation therapy (SRT) for stage I non-small cell lung cancer (NSCLC): 8-year results of 50 initial patients.
Purpose/Objective: SRT is highly effective for brain metastases from NSCLC. As such, primary lesions of NSCLC may also be treated effectively by similar focal high dose SRT.
Materials/Methods: Between October 1994 and June 1999, 50 patients with pathologically proven Stage I NSCLC were treated by CT guided SRT. Of these 21 were medically inoperable and the remainder refused surgery. In most patients, SRT was 50–60 Gy in 5–10 fractions for 1–2 weeks. Eighteen patients also received conventional RT of 40–60 Gy before SRT.
Results: A median follow-up period of living patients was longer than 5 years (range: 45–90 months). 26 patients were alive and disease free, 2 were alive with disease, 10 died of disease, and 12 died intercurrently. Local progression was observed in 3 patients. The 5-year overall survival rate was 58% in all 50 patients, and 72% in 29 patients who refused surgery. No definite adverse effects related to the treatment were not observed, except for 2 patients with a minor bone fracture and 6 patients with temporary pleural pain.
Conclusions: CT-guided SRT was very safe and effective for stage I NSCLC. Additional studies are warranted to verify the efficacy of this new approach.
論文複写へ 癌リンクへ 癌辞典へ 